Former Pharmacyclics CEO raises $75M Series B for new immunotherapy startup Corvus
Corvus Pharma, the brainchild of former Pharmacyclics CEO Richard Miller, just raised a $75 million Series B for its line of checkpoint inhibitor drugs.
corvus pharma